Cargando…
Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR
We reported a relevant activity of the combination between sorafenib and octreotide long-acting release (LAR) in advanced hepatocellular carcinoma (HCC) patients. In this work, we have studied if oxidative stress in both serum and peripheral blood mononuclear cells (PBMC) and pERK activation status...
Autores principales: | Caraglia, M, Giuberti, G, Marra, M, Addeo, R, Montella, L, Murolo, M, Sperlongano, P, Vincenzi, B, Naviglio, S, Prete, S Del, Abbruzzese, A, Stiuso, P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3122065/ https://www.ncbi.nlm.nih.gov/pubmed/21525937 http://dx.doi.org/10.1038/cddis.2011.34 |
Ejemplares similares
-
Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview
por: Marra, Monica, et al.
Publicado: (2011) -
Everolimus in combination with octreotide LAR in thymic atypical carcinoid
por: Sakane, Tadashi, et al.
Publicado: (2023) -
Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers
por: Tiberg, Fredrik, et al.
Publicado: (2015) -
A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma
por: Addeo, Raffaele, et al.
Publicado: (2010) -
Erratum to: A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma
por: Addeo, Raffaele, et al.
Publicado: (2010)